InterCure Stock
InterCure Ltd.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- CEO
- Alexander Rabinovich
- Employees
- 285
- Market cap
- $54 M
- IPO
- 28/01/2019
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's…
InterCure stock: price history
1D
-1.7%
1W
-11.6%
1M
-13.9%
6M
+18.7%
YTD
+0.4%
1Y
-40.6%
2Y
-48.1%
5Y
-87.1%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~42% weaker price swings than usual
Ask the agents about InterCure
Analyst assessment of InterCure
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
No current analyst ratings available.
InterCure stock metrics
P/E
-4.32
P/B
0.38
EV/EBITDA
-5.5
RETURN ON EQUITY
-4.3%
NET MARGIN
-24.3%
DEBT/EQUITY
0.46
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
60.8%
FLOAT SHARES
7,205,372
AVG. DAILY VOLUME (30D)
4,878
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about InterCure stock
What does InterCure do?
InterCure Ltd. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Israel.
The CEO is Alexander Rabinovich, the company employs around 285 people.
The IPO was on 28/01/2019; the stock trades on NASDAQ under the ticker INCR.
When does InterCure report next?
Around past earnings, price swings were roughly -42% stronger than usual.
Does InterCure pay a dividend?
No, InterCure currently does not pay a dividend.
Which stocks are comparable to InterCure?
Comparable stocks include Teva Pharmaceutical Industries, Merck, Takeda Pharmaceutical Company, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
How can I get InterCure stock analyzed?
Clicking "Analyze stock" lets five strategies assess InterCure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.